View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 19, 2021

Celltrion’s regdanvimab shows neutralising potency against Covid-19

Celltrion’s regdanvimab (CT-P59) shows neutralising potency against emerging Covid-19 virus variants.

Celltrion has reported that its regdanvimab (CT-P59) demonstrated neutralising potency against emerging SARS-CoV-2 variants first detected in New York, US (B.1.526), Nigeria (B.1.525) and India (B.1.617).

Regdanvimab is a monoclonal antibody being developed as a Covid-19 treatment candidate.

The Korea Disease Control and Prevention Agency (KDCA) reviewed the test by merging the antibody with New York, Nigeria and Brazil (P.1) variants. The host cell was then infected with this combination to detect regdanvimab’s neutralising effect against the variants.

According to the data, the treatment candidate showed a strong neutralising effect against the New York and Nigeria variants.

In an in-vitro pseudo virus assay, the candidate induced neutralising titers against the Indian variant.

Celltrion intends to analyse neutralising titers against other emerging strains, including the Brazil variant, to fight the pandemic as the virus is evolving.

CT-P59 could so far neutralise the SARS-CoV-2 variants first detected in the UK (B.1.1.7), California, US (B.1.427/B.1.429), Brazil (P.2), apart from the six earlier known variant genome mutations (variants S·L·V·G·GH·GR).

Last month, Celltrion reported preliminary results from a pre-clinical study, which showed regdanvimab neutralised the South African variant (B.1.351) of SARS-CoV-2 in an in vivo model.

Celltrion Healthcare Medical and Marketing division head Dr HoUng Kim said: “We are encouraged by these results, which reinforce our confidence that CT-P59 should be effective against these newly detected variants.

“Monoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate Covid-19.”

A Phase III clinical trial to assess efficacy and safety of the treatment candidate has enrolled more than 1,300 subjects in 13 countries including the US, Spain and Romania.

In a separate development, the Center for International Blood and Marrow Transplant Research (CIBMTR) has commenced a large observational study to assess the safety, efficacy and response durability to Covid-19 vaccines in patients with haematological malignancies and non-malignant blood diseases.

Carried out in partnership with the Blood and Marrow Transplant Clinical Trials Network, the study will enrol 732 subjects who were given hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR) T-cell therapy in the past 12 months.

Participants should also have received a Covid-19 vaccine.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena